ADC THERAPEUTICS SA
22Patents
22Active
22Granted
48Portfolio score
Filing activity: Nov 3, 2009 → Mar 18, 2022 · 1 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9931414B2 | Pyrrolobenzodiazepine-antibody conjugates | Chemistry; Metallurgy | 7 | Active |
| US9931415B2 | Pyrrolobenzodiazepine-antibody conjugates | Chemistry; Metallurgy | 6 | Active |
| US10017580B2 | Humanized anti-Tn-MUC1 antibodies and their conjugates | Emerging Cross-Sectional Technologies | 6 | Active |
| US9919056B2 | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates | Emerging Cross-Sectional Technologies | 6 | Active |
| US10544223B2 | Combination therapy with an anti-axl antibody-drug conjugate | Chemistry; Metallurgy | 4 | Active |
| US10780096B2 | Pyrrolobenzodiazepine-antibody conjugates | Emerging Cross-Sectional Technologies | 4 | Active |
| US9828426B2 | Antibodies against kidney associated antigen 1 and antigen binding fragments thereof | Chemistry; Metallurgy | 2 | Active |
| US11160872B2 | Pyrrolobenzodiazepine-antibody conjugates | Chemistry; Metallurgy | 2 | Active |
| US11318211B2 | Dosage regimes for the administration of an anti-CD19 ADC | Chemistry; Metallurgy | 1 | Active |
| US10722594B2 | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates | Emerging Cross-Sectional Technologies | 1 | Active |
| US10799596B2 | Pyrrolobenzodiazepine-antibody conjugates | Chemistry; Metallurgy | 1 | Active |
| US11596696B2 | Combination therapy with an anti-CD25 antibody-drug conjugate | Chemistry; Metallurgy | 1 | Active |
| US11976122B2 | Anti-IL13Rα2 antibodies | Chemistry; Metallurgy | 0 | Active |
| US10597450B2 | Antibodies against kidney associated antigen 1 and antigen binding fragments thereof | Chemistry; Metallurgy | 0 | Active |
| US11938192B2 | Dosage regimes for the administration of an anti-CD19 ADC | Chemistry; Metallurgy | 0 | Active |
| US9855291B2 | Anti-kidney associated antigen 1 (KAAG1) antibodies | Chemistry; Metallurgy | 0 | Active |
| US11702473B2 | Site-specific antibody-drug conjugates | Emerging Cross-Sectional Technologies | 0 | Active |
| US11690918B2 | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates | Emerging Cross-Sectional Technologies | 0 | Active |
| US11084872B2 | Method for treating breast cancer | Chemistry; Metallurgy | 0 | Active |
| US11813335B2 | Pyrrolobenzodiazepine-antibody conjugates | Chemistry; Metallurgy | 0 | Active |
| US11426467B2 | Dosage regimes for the administration of an anti-CD25 ADC | Human Necessities | 0 | Active |
| US11384098B2 | Pyrrolobenzodiazepine-antibody conjugates | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.